Update on Eudamed and its implications for vigilance in the EU

This will be a very short post, because everything I could write down on the subject is in the interview I had with Ashley Yeo of Scrip Regulatory Affairs, that kindly consented to publication of the article on my website, so here it is. It puts current and future vigilance initiaties, including the Eudamed database, in the perspective of the ongoing fall-out of the PIP scandal and contains some speculative predictive statements about where things are going.


Navigate through our knowledgebase

Related articles

Article

Date of Entry into Force plus three years and a little bit

 Last week  we went past DoE (Date of Entry into force) of the MDR plus three years, and the date on which the MDR was supposed to have become applicable. As you,…

Read more

Article

Labeling and Advertising of Alternative Protein

Sneak peek of Vitafoods Protein Summit Consumers nowadays tend to include more and more plant-based products into their diet. For instance, a study ordered by DuPont Nutrition established double digits of growth for non-dairy ice-cream, dairy and cheese during the year preceding June 2018.  More recently, NPR published an overview demonstrating which products were most […]

Article

Towards 100 % recyclable or re-usable plastic food packaging in 10 years

What would food be without packaging? And what does packaging mostly consist of? Of course: plastic! To date, only few other materials have proved as reliable for food packaging as plastic. At the same time, we know that plastic has many disadvantages for the environment. Read this blogpost to be informed on the most important […]